First publication of 10-year survival rate for pediatric/AYA cancer patients

Based on data on people diagnosed with cancer at cancer centers nationwide, the National Cancer Center has calculated the 10-year survival rate for children and patients in their late teens to 30s, known as the AYA generation. were compiled and published for the first time.

The National Cancer Center analyzed data on more than 360,000 people diagnosed with cancer at cancer centers nationwide in 2011. For the first time, we have calculated the survival rate 10 years after starting treatment for AYA patients aged 39 years.

When calculating the 10-year survival rate using an internationally used method, the survival rate

for childhood cancers

is 91.5% for lymphoma,

86.6% for leukemia, and

71.7% for brain tumors, and

for cancers of the AYA generation , it is

91.5%. Cervical and uterine cancer accounted for 87.7%,

breast cancer at 84.0%,

and brain and spinal cord tumors at 78.2%.

Furthermore, when we compared survival rates after 5 and 10 years, we found that for childhood cancers, there was not much of a decline in survival rates, but for cancers in the AYA generation, for example, breast cancer survival rates after 10 years were significantly lower. The rate differed depending on the type of cancer, with the rate decreasing by more than 6 points.

On the other hand, the overall survival rate after 10 years for all ages, including adults, was 53.5%, which is almost the same as the previous result announced last year.

Dr. Taisuke Ishii of the National Cancer Center said, ``Until now, there has been limited data on survival rates for childhood cancers and cancers in the AYA generation.This study has confirmed that childhood cancers have a good outlook after treatment. The AYA generation requires different types of support depending on the type of cancer they have.I hope this data will serve as basic information when considering support measures.''

Childhood cancer AYA generation cancer survival rate by type

The 5- and 10-year survival rates for each type of cancer for childhood cancers and AYA generations are as follows.

The "actual" survival rate includes all deaths, regardless of cause of death.

In addition, "net" is a survival rate calculated using a calculation method widely used internationally to understand the impact of cancer in more detail, and is called "net survival."

This time, the National Cancer Center has released only actual numbers regarding survival rates after 5 years.

childhood cancer

Leukemia

▽ 5 years actual measurement: 88.4%

▽ 10 years actual measurement: 86.2%

▽ 10 years net: 86.6%

Lymphoma

▽ 5 years actual measurement: 92.4%

▽ 10 years actual measurement: 91.4%

▽ 10 years net: 91.5%

Brain tumor

▽ 5 years actual measurement: 73.5%

▽10 years actual measurement: 71.5%

▽10 years net: 71.7%

Neuroblastoma

▽5 years actual measurement: 73.3%

▽10 years actual measurement: 67.9%

▽10 years net: 68.5%

Bone tumor

▽5 years actual measurement: 73.6%

▽ 10 years actual measurement: 71.4%

▽ 10 years net: 71.4%

Soft tissue tumor

▽ 5 years actual measurement: 75.4%

▽ 10 years actual measurement: 73.5%

▽ 10 years net: 73.7%

Germ cell tumor

▽ 5 years actual measurement: 96.5%

▽ 10 years actual measurement :95.3%

▽10 years net: 95.6%

Other cancers

▽5 years actual measurement: 97.1%

▽10 years actual measurement: 91.1%

▽10 years net: 91.2%

Cancer in the AYA generation

Leukemia

▽ 5 years actual measurement: 72.8%,

▽ 10 years actual measurement: 70.1%,

▽ 10 years net: 70.6%,

Lymphoma

▽ 5 years actual measurement: 88.0%,

▽ 10 years actual measurement: 86.0%,

▽ 10 years net: 86.6%,

Brain/spinal cord tumor

▽ 5 years actual measurement: 83.5%

▽ 10 years actual measurement: 77.8%

▽ 10 years net: 78.2%

Bone/cartilage tumor

▽ 5 years actual measurement: 68.3%

▽ 10 years actual measurement: 62.5%

▽ 10 years net: 62.9%

Soft tissue sarcoma

▽ 5 years actual measurement: 75.5%

▽ 10 years actual measurement: 70.5%

▽ 10 years net: 70.9%

Germ cell tumor, etc.

▽ 5 years actual measurement: 93.7%

▽ 10 years actual measurement: 93.6%

▽ 10 years net: 94.3%

black Tumor/skin cancer

▽ 5 years actual measurement: 82.9%

▽ 10 years actual measurement: 79.5%

▽ 10 years net: 80.1%

Thyroid cancer

▽ 5 years actual measurement: 99.4%

▽ 10 years actual measurement: 98.8%

▽ 10 years net: 99.4%

Other cancers of the scalp

▽ 5 years actual measurement: 83.3%

▽ 10 years actual measurement: 78.7%

▽ 10 years net: 79.2%

Lung/bronchial cancer

▽ 5 years actual measurement: 46.3%

▽ 10 years actual measurement: 38.8%

▽ 10 years net: 39.1%

breast cancer

▽ 5 years actual measurement: 90.0%

▽ 10 years actual measurement: 83.5%

▽ 10 years net: 84.0%

kidney cancer

▽ 5 years actual measurement: 90.3%

▽ 10 years actual measurement: 87.6%

▽ 10 years net: 88.3%

Bladder cancer

▽ 5 years actual measurement: 79.1%

▽ 10 years actual measurement: 71.5%

▽ 10 years net: 72.0%

Gonadal cancer

▽ 5 years actual measurement: 81.0%

▽ 10 years actual measurement: 75.4%

▽ 10 years net: 75.9 %

Cervical cancer/uterine cancer

▽ 5 years actual measurement: 88.6%

▽ 10 years actual measurement: 87.2%

▽ 10 years net: 87.7%

Colorectal cancer

▽ 5 years actual measurement: 75.2%

▽ 10 years actual measurement: 69.9%

▽ 10 years Net: 70.5%

gastric cancer

▽ 5 years actual measurement: 61.8%

▽ 10 years actual measurement: 59.2%

▽ 10 years net: 59.7%

Intrahepatic bile duct cancer

▽ 5 years actual measurement: 43.1%

▽ 10 years actual measurement: 36.1%

▽ 10 years net: 36.4%

Gastrointestinal cancers such as pancreatic cancer

▽ 5-year actual measurement: 50.1%

▽ 10-year actual measurement: 43.6%

▽ 10-year net: 43.9%

Data by cancer type and stage

Data by cancer type and stage for all ages, including adults.

All of these figures are based on a survival rate called ``net survival,'' which is calculated by estimating only those who died due to cancer.

Listed in descending order of overall survival rate.

Papillofollicular thyroid cancer

Stage 1: 97.1%

Stage 2: 89.2%

Stage 3: 95.0% Stage

4: 74.8%

Overall: 90.2%

Prostate cancer

Stage 1: 93.7%

Stage 2: 95.4%

▽Stage 3: 87.3%

▽Stage 4: 37.4%

▽Overall: 85.4%

Female Breast Cancer

▽Stage 1: 94.1%

▽Stage 2: 86.6%

▽Stage 3: 62.7%

▽Stage 4: 16.9%

▽Overall: 82.9%

Uterus Body cancer

Stage 1: 91.9%

Stage 2: 82.6%

Stage 3: 65.2% Stage

4: 17.4%

Overall: 79.6%

Cervical cancer

Stage 1: 91.6%

Stage 2: 71.8%

Stage 3: 52.5%

▽Stage 4: 19.0%

▽Overall: 68.1

Kidney cancer

▽Stage 1: 82.8%

▽Stage 2: 68.7%

▽Stage 3: 55.7%

▽Stage 4: 7.3%

▽Overall: 66.4%

Laryngeal cancer

▽ Stage 1: 74.2%

▽Stage 2: 68.7%

▽Stage 3: 41.8%

▽Stage 4: 32.4%

▽Overall: 60.2%

Colorectal cancer

▽Stage 1: 80.4%

▽Stage 2: 69.8%

▽Stage 3: 61.2%

▽ Stage 4: 11.1%

▽Overall: 57.9%

Gastric cancer

▽Stage 1: 77.6%

▽Stage 2: 48.9%

▽Stage 3: 32.0%

▽Stage 4: 5.9%

▽Overall: 56.8%

Ovarian cancer

▽Stage 1: 85.5%

▽ Stage 2: 61.8%

▽Stage 3: 29.2%

▽Stage 4: 14.6%

▽Overall: 53.6%

Bladder cancer

▽Stage 1: 65.4%

▽Stage 2: 39.1%

▽Stage 3: 33.6%

▽Stage 4: 13.9%

▽ Overall: 49.8%

renal pelvic and ureteral cancer

▽ Stage 1: 63.0%

▽ Stage 2: 49.5%

▽ Stage 3: 40.2%

▽ Stage 4: 7.4%

▽ Overall: 34.6%

non-small cell lung cancer

▽ Stage 1: 62.9%

▽ Stage 2: 28.7%

▽Stage 3: 12.8%

▽Stage 4: 2.3%

▽Overall: 31.5%

Gallbladder cancer

▽Stage 1: 63.8%

▽Stage 2: 16.2%

▽Stage 3: 4.2%

▽Stage 4: 1.1%

▽ Overall: 21.7%

hepatocellular carcinoma

▽ Stage 1: 34.0%

▽ Stage 2: 20.5%

▽ Stage 3: 7.4%

▽ Stage 4: 1.0%

▽ Overall: 22.6%

Intrahepatic bile duct cancer

▽ Stage 1: 34.3%

▽ Stage 2: 21.6%

▽Stage 3: 5.0%

▽Stage 4: 0.8%

▽Overall: 11.0%

Small cell lung cancer

▽Stage 1: 32.5%

▽Stage 2: 17.1%

▽Stage 3: 8.5%

▽Stage 4: 1.2%

▽Overall: 7.4%

Pancreatic cancer

▽Stage 1: 31.4%

▽Stage 2: 10.3%

▽Stage 3: 3.2%

▽Stage 4: 0.6%

▽Overall: 5.8%

10 by cancer type Detailed results, including year-on-year survival rates, will be published on the ``Cancer Information Service'' website operated by the National Cancer Center.